Ovid Therapeutics rises as epilepsy drug shows clean safety

Shares of biotech firm Ovid Therapeutics OVID.O rise about 16% to $2.33 premarket

Says experimental epilepsy drug OV329 showed a clean safety profile in an early-stage study

Volunteers given a 7 mg dose reported no treatment-related side effects; other events were mild and short-lived - OVID

Says no signs of eye problems, a known risk with older drugs in the same class

Plans a mid-stage trial in focal onset seizures, a common form of epilepsy, in Q2

Also plans studies in rare childhood seizure disorders, including tuberous sclerosis complex and infantile spasms

Raises $60 mln in a private funding round to support the studies

Shares gained ~75% in 2025